Condition: Dilated Cardiomyopathy (DCM) · Heart Failure · Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy. Previous clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion is safe and whether it can further improve cardiac function in this patient population.
This description comes directly from the study's public registry record.
Jiamin Li, MD · 86-18868112006 · 21818216@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang / 浙江, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07516288